m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01468)
Name
2-Propanol, Isopropanol
Synonyms
Isopropyl alcohol; isopropanol; 2-Propanol; Propan-2-ol; 67-63-0; 2-Hydroxypropane; Hartosol; Avantine; Alkolave; Dimethylcarbinol; sec-Propyl alcohol; Takineocol; Petrohol; Alcojel; Avantin; i-Propanol; 1-Methylethanol; 2-Propyl alcohol; Propol; Lutosol; Isohol; Alcolo; Lavacol; Alcosolve 2; Imsol A; 1-Methylethyl alcohol; Arquad DMCB; Alcosolve; Spectrar; n-Propan-2-ol; i-Propylalkohol; Combi-schutz; i-Propyl alcohol; Isopropyl alcohol, rubbing; Iso-propylalkohol; Alcool isopropilico; Visco 1152; Alcool isopropylique; Sterisol hand; Isopropyl Alcohol
    Click to Show/Hide
Status
Investigative
Structure
Formula
C3H8O
InChI
1S/C3H8O/c1-3(2)4/h3-4H,1-2H3
InChIKey
KFZMGEQAYNKOFK-UHFFFAOYSA-N
PubChem CID
3776
TTD Drug ID
D0W7LK
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Nitric oxide synthase endothelial (NOS3)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Nitric oxide synthase endothelial (NOS3) is a therapeutic target for 2-Propanol, Isopropanol. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 2-Propanol, Isopropanol through regulating the expression of Nitric oxide synthase endothelial (NOS3). [1], [2]
Tumor necrosis factor (TNF)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tumor necrosis factor (TNF) is a therapeutic target for 2-Propanol, Isopropanol. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 2-Propanol, Isopropanol through regulating the expression of Tumor necrosis factor (TNF). [3], [4]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tumor necrosis factor (TNF) is a therapeutic target for 2-Propanol, Isopropanol. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of 2-Propanol, Isopropanol through regulating the expression of Tumor necrosis factor (TNF). [4], [5]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tumor necrosis factor (TNF) is a therapeutic target for 2-Propanol, Isopropanol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Propanol, Isopropanol through regulating the expression of Tumor necrosis factor (TNF). [4], [6]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tumor necrosis factor (TNF) is a therapeutic target for 2-Propanol, Isopropanol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-Propanol, Isopropanol through regulating the expression of Tumor necrosis factor (TNF). [4], [6]
YTH domain-containing family protein 3 (YTHDF3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tumor necrosis factor (TNF) is a therapeutic target for 2-Propanol, Isopropanol. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of 2-Propanol, Isopropanol through regulating the expression of Tumor necrosis factor (TNF). [3], [4]
References
Ref 1 N6-Methyladenosine Demethylase FTO (Fat Mass and Obesity-Associated Protein) as a Novel Mediator of Statin Effects in Human Endothelial Cells. Arterioscler Thromb Vasc Biol. 2022 May;42(5):644-658. doi: 10.1161/ATVBAHA.121.317295. Epub 2022 Mar 17.
Ref 2 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.
Ref 3 N6-methyladenosine reader YTH N6-methyladenosine RNA binding protein 3 or insulin like growth factor 2 mRNA binding protein 2 knockdown protects human bronchial epithelial cells from hypoxia/reoxygenation injury by inactivating p38 MAPK, AKT, ERK1/2, and NF-KappaB pathways. Bioengineered. 2022 May;13(5):11973-11986. doi: 10.1080/21655979.2021.1999550.
Ref 4 A novel anti-rheumatic drug suppresses tumor necrosis factor-alpha and augments interleukin-10 in adjuvant arthritic rats. Eur J Pharmacol. 2000 Dec 15;409(3):331-5. doi: 10.1016/s0014-2999(00)00866-9.
Ref 5 METTL14 promotes glomerular endothelial cell injury and diabetic nephropathy via m6A modification of Alpha-klotho. Mol Med. 2021 Sep 9;27(1):106. doi: 10.1186/s10020-021-00365-5.
Ref 6 Mettl3 inhibits the apoptosis and autophagy of chondrocytes in inflammation through mediating Bcl2 stability via Ythdf1-mediated m(6)A modification. Bone. 2022 Jan;154:116182. doi: 10.1016/j.bone.2021.116182. Epub 2021 Sep 13.